Bionova Scientific entered a manufacturing alliance with Syenex to expand global access to plasmid DNA for genetic medicines and next‑generation delivery systems. Bionova will serve as Syenex’s preferred manufacturing partner and will broaden off‑the‑shelf and custom plasmid offerings spanning R&D to GMP, including backbones and helper plasmids used in LVV and mRNA template production. Bionova highlights an IS‑free bacterial host architecture designed to reduce plasmid instability and improve batch consistency—key risks for downstream vector yields and regulatory robustness. The alliance aims to de‑risk plasmid supply for sponsors developing lentiviral vectors, in vivo LVV and other genetic medicine formats. Reliable, scalable plasmid manufacturing is a critical enabler for cell and gene therapy programs; the partnership addresses a frequent bottleneck in vector production and supports a smoother transition from research to clinic.